En español

NIDA and Lightlake Therapeutics partner to expand access to medication to treat opioid overdose


August 21, 2013

From concept to medication to treatment graphic

NIDA and Lightlake Therapeutics Inc., a biopharmaceutical company developing novel treatments for addictions and conducting clinical trials with intranasal naloxone for the treatment of binge eating disorder, have entered into a partnership to apply this technology towards the treatment of opioid overdose. Clinical trials are expected to begin fall 2013.

Naloxone is an injectable medicine that can rapidly reverse the overdose of prescription and illicit opioids. An intranasal delivery system for naloxone could widely expand its availability and use in preventing opioid overdose deaths, a public health problem of epidemic proportion in the U.S.

For more on the role of naloxone in preventing opioid overdose deaths, see: https://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm472923.htm.

To learn more about NIDA’s medications development program, go to: www.drugabuse.gov/about-nida/organization/divisions/division-pharmacotherapies-medical-consequences-drug-abuse-dpmcda.

For more information, contact the NIDA press office at media@nida.nih.gov or 301-443-6245.

NIDA Press Office

About the National Institute on Drug Abuse (NIDA): The National Institute on Drug Abuse (NIDA) is a component of the National Institutes of Health, U.S. Department of Health and Human Services. NIDA supports most of the world’s research on the health aspects of drug use and addiction. The Institute carries out a large variety of programs to inform policy, improve practice, and advance addiction science. Fact sheets on the health effects of drugs and information on NIDA research and other activities can be found at www.drugabuse.gov, which is now compatible with your smartphone, iPad or tablet. To order publications in English or Spanish, call NIDA’s DrugPubs research dissemination center at 1-877-NIDA-NIH or 240-645-0228 (TDD) or email requests to drugpubs@nida.nih.gov. Online ordering is available at drugpubs.drugabuse.gov. NIDA’s media guide can be found at www.drugabuse.gov/publications/media-guide/dear-journalist, and its easy-to-read website can be found at www.easyread.drugabuse.gov. You can follow NIDA on Twitter and Facebook.

About the National Institutes of Health (NIH): NIH, the nation’s medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.

NIH. . .Turning Discovery Into Health®

News Releases








Get this Publication

    Cite this article

    NIDA. (2013, August 21). NIDA and Lightlake Therapeutics partner to expand access to medication to treat opioid overdose. Retrieved from https://www.drugabuse.gov/news-events/news-releases/2013/08/nida-lightlake-therapeutics-partner-to-expand-access-to-medication-to-treat-opioid-overdose

    press ctrl+c to copy
    Receive Latest Science Articles in your Email!
    You will only receive messages related to Latest Science